Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Exports to Surpass Retail Sales (India)

This article was originally published in PharmAsia News

Executive Summary

India's pharmaceutical industry will export more than they sell domestically when fiscal 2007 numbers are added up, says the Indian Pharmaceutical Alliance (IPA). In fact IPA predicts India pharmaceutical exports will grow by 35 percent annually during the next five years, compared to 16 percent for Indian retail sales, widening this export-domestic gap even more. In the last full fiscal year, pharmaceutical exports of Indian companies totaled RS 24,600 crore, which is slightly below their domestic retail sales of RS 27,903 crore. "Export growth is driven by growing dependence on generics across the world to contain health expenditure, acceptance of Indian generic drugs, aggressive expansion of Indian companies in international markets, and entry of smaller companies into exports," commented IPA secretary general D.G. Shah. Furthermore, patent drugs sales totaling around $100 billion today will see their patents expire between now and 2012, presenting generic drug makers with even more opportunities worldwide. (Click here for more

You may also be interested in...



US FDA Oncology AdComm's Pediatric Study Reviews Go Virtual

ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.

Merck Is Counting On Keytruda To Establish Its Anti-TIGIT Drug

Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.

EU Unveils Ambitions To ‘Future-Proof’ Entire Drug Regulatory Framework

Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel